When NNVC finally markets its drug for EKC, what will be the annual revenue? Now, consider Rabicide and its $300 million annual market. Add to that the stockpile drugs, beginning with nanoviricides for Ebola and Marburg. Then there is simply FluCide and the 300k cases a year where influenza adds deadly complications to pre-existing health conditions. Now consider the annual revenue from HiviCide, and then there is Hepititis C.
Now consider this, after 2009 the company plans to bring one drug to market every 6 months with ten more years remaining on the patent rights.
In 7 years, don't you think an $11 billion market cap might be too low?
News 
Market Data 
Discover 
